Furthermore, since ATCVs are “antigen agnostic,” they could be used in the management of any subtype of breast cancer including triple-negative breast cancers (TNBCs), which lack hormone and human epidermal growth factor receptor 2 (HER2) receptors, the usual targets for breast cancer therapies. The gene discussed is ERBB2; the disease is breast carcinoma.